# Apixaban in Thrombocytopenia

> **NCT06886516** · EARLY_PHASE1 · RECRUITING · sponsor: **Rushad Patell** · enrollment: 30 (estimated)

## Conditions studied

- Deep Vein Thrombosis
- Pulmonary Embolism and Thrombosis
- Thrombocytopenia
- Recurrent Venous Thromboembolism

## Interventions

- **DRUG:** Apixaban

## Key facts

- **NCT ID:** NCT06886516
- **Lead sponsor:** Rushad Patell
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-28
- **Primary completion:** 2027-07-01
- **Final completion:** 2029-07-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06886516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06886516, "Apixaban in Thrombocytopenia". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06886516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*